Background {#Sec1}
==========

Patients diagnosed with stage-I non-small cell lung cancer (NSCLC) are most likely to be cured by surgical radical resection. Lymph node dissection is an important part of this procedure that can improve the prognosis of the patients in stage-I \[[@CR1]\]. However, selection of the best strategy for lymph node dissection remains controversial.

In general, lymph nodes with short-axis diameters of \> 1 cm as seen on CT scan are considered by the radiologists to represent metastasis when other reasons causing lymph node enlargement, such as chronic inflammation and tuberculosis, are excluded. Unfortunately, the diagnostic accuracy of CT scan for the preoperative lymph node stage is only 45--79% \[[@CR2]--[@CR6]\]. Also, 12--17% of patients pathologically diagnosed as N2 are preoperatively considered as N0. Skipping metastasis is also found in a part of these patients, as their CT scan results revealed lymph nodes with short-axis diameters of \< 1 cm \[[@CR4], [@CR5], [@CR7]\]. With technological developments, many methods, such as positron emission tomography, mediastinoscopy, and endoscopic ultrasound-guided fine-needle aspiration, are used to make accurate diagnosis when the surgeon ambiguously confirms preoperative lymph node metastasis. However, owing to the invasive nature of the procedure and the associated expenses, these diagnostic methods could not be routinely used for screening patients with clinical stage-I disease. Also, these procedures yield a considerable number of false-negative results and complications \[[@CR8]--[@CR10]\].

Although systematic nodal dissection can guarantee an accurate pathological nodal (pN) staging with a sufficient quantity of lymphatic tissue, the occurrence of postoperative complications will increase. For early stage patients, getting accurate patterns of lymph node dissection will decrease the postoperative complications and speed-up the patient recovery.

Regional lymph nodes attract attention for less invasive intraoperative lymph node dissection in early stage patients. We can classify the lymph nodes into four regional lymph nodes: Interlobar lymph node, Hilar lymph nodes, Lobe-specific mediastinal lymph nodes and Lobe non-specific mediastinal lymph nodes. Skipping mediastinal metastasis is defined as the metastasis of lobe nonspecific mediastinal lymph nodes, and it is confirmed pathologically by the absence of lobe specific mediastinal lymph node metastasis. The concept of lobe specific mediastinal lymph node is based on the lobe specificity of the lymphatic spread, and the characteristic lymph nodal metastasis patterns could be derived from different primary tumor locations \[[@CR11], [@CR12]\]. Surgeons can design an accurate strategy for lymph node dissection according to the regulation of regional lymph node metastasis.

However, each patient exhibits different clinical and pathological characteristics. Several studies have demonstrated that the incidence of lymph node metastasis differs according to individual clinical parameters and histologic components within the tumor \[[@CR13]--[@CR17]\]. This patient heterogeneity finally affects the pattern of regional lymph node metastasis in early stage lung cancer.

The goal of this study was to identify the clinicopathologic characteristics that could predict the differences in metastasis among the various regional lymph nodes and to discuss the patterns for patients intraoperatively diagnosed with stage-I NSCLC. These clinicopathologic predictors will probably provide surgeons with useful information to select the appropriate lymph node dissections, especially for early stage patients.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

A total of 595 patients who consecutively underwent surgical resection for primary lung cancer at our hospital from January 2015 to December 2017 were reviewed retrospectively. The records of patients intraoperatively diagnosed with stage-I NSCLC who underwent lobectomy or segmentectomy with complete lymph node dissection as per the nomenclature were selected for this study. All patients met the criteria for stage-I NSCLC based on the new International Staging System for NSCLC (National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2014: Staging Non-Small Cell Lung Cancer) \[[@CR12]\]. We excluded patients who exhibited any one of the following conditions: 1) preoperative tumor size \> 4 cm and lymph node \> 1 cm at the largest diameter on CT imaging or evidence of distant metastasis; 2) preoperative chemotherapy or radiotherapy; 3) previous or coexistent tuberculosis or malignant disease; 4) complete lymph node dissection that did not meet the current standards (i.e., all lymph node stations, including right-hand stations 2--4 and 7--9 and left-hand stations 2--9); 5) synchronous lung cancers, or 8) intraoperative frozen rapid pathological results depicting tumor size \> 4 cm in the largest diameter.

Patients were preoperatively assessed with chest X-ray, chest and upper abdominal CT scan, brain magnetic resonance imaging, and bone scintigraphy. CT scan was used for preoperative N-staging. The approach for primary lung cancer resection was video-assisted thoracic surgery.

Tissue specimens contained pulmonary nodules and lymph nodes. Pulmonary nodules were analyzed using rapid frozen section in the pathology department of our medical center. The remaining nodules and lymph nodes were fixed using 10% formalin, and conventional formalin-fixed, paraffin-embedded pathological tests were performed.

Statistical analysis {#Sec4}
--------------------

The baseline patient characteristics were summarized in percent for categorical variables. The significance of associations with the outcome of lymph nodal metastases was first evaluated using a univariate logistic analysis (*P* \< 0.20). These significant variables were further analyzed by multivariable analysis as independent predictors for lymph node metastasis (*P* \< 0.05). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Statistical analyses were performed using STATA software, release 13.

Results {#Sec5}
=======

Patient characteristics {#Sec6}
-----------------------

A total of 595 patients intraoperatively diagnosed with stage-I NSCLC were included in this study. Table [1](#Tab1){ref-type="table"} displays the patient demographics and clinical characteristics. The mean age was 60 years (range 25--87 years). Among the patients, 304 (51.1%) patients had a maximum tumor diameter of [≤]{.ul}1.6 cm and 284 (47.7%) had a diameter of \> 1.6 cm. The tumor originated in the right upper lobe in 181 patients (30.4%), right middle lobe in 28 (4.7%), right lower lobe in 84 (14.1%), left upper lobe in 135 (22.7%), left lower lobe in 87 (14.6%), ipsilateral mixed lobes in 48 (8.1%), and bilateral mixed lobes in 26 (4.4%). Histologically, the tumors in 442 patients (74.3%) were identified as adenocarcinoma, in 62 (10.4%) as squamous cell carcinoma, in 73 (12.3%) as in situ adenocarcinoma, and in 16 (2.7%) as others. The tumor differentiation included stage-I (125 patients, 21.0%), I--II (82 patients, 13.8%), II (139 patients, 23.4%), II--III (137 patients, 23.0%), and III (61 patients, 10.3%). Pulmonary membrane invasion was present in 58 patients (9.7%), bronchial mucosa and cartilage invasion in 54 (9.1%), vascular invasion in 44 (7.4%), and nerve invasion in 13 (2.2%). The number of patients with CEA ≤ 2.21 ng/mL was 253 (42.5%) and \> 2.21 ng/mL was 254 (42.7%); albumin ≤43.1 g/L was 289 (48.6%) and \> 43.1 g/L was 288 (48.4%).Table 1Patient demographics and clinical characteristics (*n* = 595)CharacteristicsValueAge (years)Median (Interquartile range)60 (25--87)  ≤ 60301 (50.6%)  \> 60294 (49.4%)Sex Female304 (51.1%) Male291 (48.9%)Maximum diameter of tumor  ≤ 1.6 cm304 (51.1%)  \> 1.6 cm284 (47.7%) Missing7 (1.2%)Position Right Upper Lobe181 (30.4%) Right Middle Lobe28 (4.7%) Right Lower Lobe84 (14.1%) Left Upper Lobe135 (22.7%) Left Lower Lobe87 (14.6%) Ipsilateral Mixed lobes48 (8.1%) Bilateral Mixed lobes26 (4.4%) Missing6 (1.0%)Pathological type Adenocarcinoma442 (74.3%) Squamous cell carcinoma62 (10.4%) Adenocarcinoma in situ73 (12.3%) Others16 (2.7%) adenosquamous carcinoma4 large cell neuroendocrine lung cancer3 metastatic colorectal cancer1 carcinoid5 sclerosing pneumocytoma1 lymphlepithelioma1 metastatic papillary thyroid cancer1 Missing2 (0.35%)Tumor differentiation No28 (4.7%) I125 (21.0%) I-II82 (13.8%) II139 (23.4%) II-III137 (23.0%) III61 (10.3%) Missing23 (3.9%)Pathological morphology No210 (35.3%) lepidic37 (6.2%) Acinar178 (29.9%) Micropapillary4 (0.7%) Papillary85 (14.3%) solid53 (8.9%) Missing28 (4.7%)Pulmonary membrane invasion No431 (72.4%) Yes58 (9.7%) Missing106 (17.8%)Bronchial mucosa and cartilage invasion No540 (90.8%) Yes54 (9.1%) Missing1 (0.2%)Vascular invasion No548 (92.1%) Yes44 (7.4%) Missing3 (0.5%)Nerve invasion No581 (97.6%) Yes13 (2.2%) Missing1 (0.2%)CEA  ≤ 2.21 ng/ml253 (42.5%)  \> 2.21 ng/ml254 (42.7%) Missing88 (14.8%)Albumin  ≤ 43.1 g/l289 (48.6%)  \> 43.1 g/l288 (48.4%) Missing18 (3.0%)

Association of Individual clinicopathologic characteristics with metastasis of different regional lymph nodes {#Sec7}
-------------------------------------------------------------------------------------------------------------

For the interlobar lymph node, univariate analysis showed that sex (OR = 1.95, 95% CI 0.88--4.30; *P* = 0.098, male patients 9.0% and female patients 4.8%), maximum diameter of the tumor (OR = 2.75, 95% CI 1.19--6.36; *P* = 0.018, \> 1.6 cm 10.0%, ≤1.6 cm 3.9%), position (*P* \< 0.0001, right lower lobe 26.2%, left lower lobe 9.0%, and bilateral mixed lobes 11.8% were higher than the other lobes), pulmonary membrane invasion (OR = 2.88, 95% CI 0.98--8.47; *P* = 0.055, present 12.5% and absent 4.7%), bronchial mucosa and cartilage invasion (OR = 2.81, 95% CI 1.07--7.40; *P* = 0.036, present 15.4% and absent 6.1%), vascular invasion (OR = 2.23, 95% CI 0.72--6.88; *P* = 0.164, present 13.3% and absent 6.5%), CEA (OR = 4.61, 95% CI 1.53--13.91; *P* = 0.007, \> 2.21 ng/mL 9.9% and ≤ 2.21 ng/mL 2.3%), and albumin (OR = 0.27, 95% CI 0.11--0.64; *P* = 0.003, ≤43.1 g/L 11.3% and \> 43.1 g/L 3.3%) were the 8 significant risk factors associated with metastasis (Table [2](#Tab2){ref-type="table"}).Table 2Univariate and multivariate logistic regression predictors of interlobar lymph node metastasisIndependents VariablesUnivariate PredictorsMultivariate PredictorsN Metastasis/N totalOdds Ratio (95% CI), *P*-valueBOdds Ratio (95% CI), *P*-valueAge (years) ≤6019/216 (8.8%)Reference \> 6010/202 (5.0%)0.54 (0.25--1.19), 0.540Sex Female10/207 (4.8%)Reference Male19/211 (9.0%)1.95 (0.88--4.30), 0.098\*Maximum diameter of tumor ≤1.6 cm8/205 (3.9%)Reference \> 1.6 cm21/209 (10.0%)2.75 (1.19--6.36), 0.018\*Position\< 0.0001\* Right Upper Lobe3/121 (2.5%)Reference Right Middle Lobe0/22 (0.0%)0.00 (0.00-), 0.998 Right Lower Lobe16/61 (26.2%)13.99 (3.89--50.30), \< 0.0001\* Left Upper Lobe1/93 (1.1%)0.43 (0.04--4.18), 0.465 Left Lower Lobe6/67 (9.0%)3.87 (0.94--16.01), 0.062\* Ipsilateral Mixed lobes1/35 (2.9%)1.16 (0.12--11.48), 0.901 Bilateral Mixed lobes2/17 (11.8%)5.24 (0.81--33.96), 0.082\*Pathological type Adenocarcinoma25/319 (7.8%)Reference Others4/98 (4.1%)0.50 (0.17--1.48), 0.209Tumor differentiation No0/102 (0.0%)Reference Yes29/302 (9.6%)171,607,233.80 (0.00-), 0.996Pathological morphology No8/140 (5.7%)Reference Yes21/262 (8.0%)1.44 (0.62--3.34), 0.398Pulmonary membrane invasion No14/296 (4.7%)Reference Yes5/40 (12.5%)2.88 (0.98--8.47), 0.055\*Bronchial mucosa and cartilage invasion No23/379 (6.1%)Reference Yes6/39 (15.4%)2.81 (1.07--7.40), 0.036\*Vascular invasion No25/387 (6.5%)Reference Yes4/30 (13.3%)2.23 (0.72--6.88), 0.164\*Nerve invasion No28/412 (6.8%)Reference Yes1/6 (16.7%)2.74 (0.31--24.29), 0.365CEA ≤2.21 ng/ml4/172 (2.3%)Reference \> 2.21 ng/ml18/182 (9.9%)4.61 (1.53--13.91), 0.007\*Albumin ≤43.1 g/l22/195 (11.3%)Reference \> 43.1 g/l7/212 (3.3%)0.27 (0.11--0.64), 0.003\*\*Only variables with *P* value less than 0.20 were included in the multivariate analysis

In the case of hilar lymph node, univariate analysis exposed that sex (OR = 1.83, 95% CI 1.06--3.16; *P* = 0.029, male patients 16.4% and female patients 9.7%), maximum tumor diameter (OR = 5.42, 95% CI 2.68--10.97; *P* \< 0.0001, \> 1.6 cm 19.9% and ≤ 1.6 cm 4.4%), position (*P* = 0.122, right lower lobe 19.1%, right middle lobe 25.0%, and ipsilateral mixed lobes 21.2% were higher than the other lobes), tumor differentiation (OR = 6.36, 95% CI 1.95--20.74; *P* = 0.002, present 16.3% and absent 3.0%), pulmonary membrane invasion (OR = 3.20, 95% CI 1.58--6.47; *P* = 0.001, present 25.5% and absent 9.6%), bronchial mucosa and cartilage invasion (OR = 5.57, 95% CI 2.94--10.56; *P* \< 0.0001, present 38.5% and absent 10.1%), vascular invasion (OR = 7.68, 95% CI 3.86--15.26; *P* \< 0.0001, present 46.3% and absent 10.1%), nerve invasion (OR = 5.90, 95% CI 1.75--19.95; *P* = 0.004, present 45.5% and absent 12.4%), CEA (OR = 9.66, 95% CI 3.74--24.90; *P* \< 0.0001, \> 2.21 ng/mL 20.1% and ≤ 2.21 ng/mL 2.5%), and albumin (OR = 0.27, 95% CI 0.11--0.64; *P* = 0.003, ≤43.1 g/L 18.2% and \> 43.1 g/L 7.0%) were the 10 significant risk factors associated with metastasis (Table [3](#Tab3){ref-type="table"}).Table 3Univariate and multivariate logistic regression predictors of hilar lymph node metastasisIndependents VariablesUnivariate PredictorsMultivariate PredictorsN Metastasis/N totalOdds Ratio (95% CI), *P*-valueBOdds Ratio (95% CI), *P*-valueAge (years) ≤ 6031/243 (12.8%)Reference \>  6033/245 (13.5%)1.07 (0.63--1.80), 0.816Sex Female23/238 (9.7%)Reference Male41/250 (16.4%)1.83 (1.06--3.16), 0.029\*Maximum diameter of tumor ≤1.6 cm10/228 (4.4%)Reference \> 1.6 cm51/256 (19.9%)5.42 (2.68--10.97), \< 0.0001\*Position0.122\* Right Upper Lobe15/157 (9.6%)Reference Right Middle Lobe5/20 (25.0%)3.16 (1.01--9.90), 0.049\* Right Lower Lobe13/68 (19.1%)2.24 (1.00--5.01), 0.050\* Left Upper Lobe16/110 (14.5%)1.61 (0.76--3.42), 0.213 Left Lower Lobe6/80 (7.5%)0.77 (0.29--2.06), 0.600 Ipsilateral Mixed lobes7/33 (21.2%)2.55 (0.95--6.86), 0.064\* Bilateral Mixed lobes2/16 (12.5%)1.35 (0.28--6.53), 0.707Pathological type Adenocarcinoma51/370 (13.8%)Reference Others13/118 (11.0%)0.77 (0.41--1.48), 0.439Tumor differentiation No3/101 (3.0%)Reference Yes60/368 (16.3%)6.36 (1.95--20.74), 0.002\*Pathological morphology No21/167 (12.6%)Reference Yes42/306 (13.7%)1.11 (0.63--1.94), 0.725Pulmonary membrane invasion No33/342 (9.6%)Reference Yes14/55 (25.5%)3.20 (1.58--6.47), 0.001\*Bronchial mucosa and cartilage invasion No44/436 (10.1%)Reference Yes20/52 (38.5%)5.57 (2.94--10.56), \< 0.0001\*1.133.11 (1.19--8.13), 0.021^\#^Vascular invasion No45/445 (10.1%)Reference Yes19/41 (46.3%)7.68 (3.86--15.26), \< 0.0001\*1.092.98 (1.14--7.81), 0.026^\#^Nerve invasion No59/477 (12.4%)Reference Yes5/11 (45.5%)5.90 (1.75--19.95), 0.004\*CEA ≤2.21 ng/ml5/197 (2.5%)Reference \> 2.21 ng/ml44/219 (20.1%)9.66 (3.74--24.90), \< 0.0001\*2.148.49 (2.49--28.97), 0.001^\#^Albumin ≤43.1 g/l45/247 (18.2%)Reference \> 43.1 g/l16/227 (7.0%)0.27 (0.11--0.64), 0.003\*\*Only variables with *P* value less than 0.20 were included in the multivariate analysis. ^**\#**^ *P* \< 0.05 Sum might not always be in total because of missing data

For the lobe specific mediastinal lymph node, univariate analysis established that sex (OR = 1.97, 95% CI 1.08--3.59; *P* = 0.028, male patients 11.1% and female patients 6.0%), maximum tumor diameter (OR = 4.76, 95% CI 2.33--9.74; *P* \< 0.0001, \> 1.6 cm 14% and ≤ 1.6 cm 3.3%), position (*P* = 0.096, right lower lobe 16.7% and right middle lobe 14.3% were higher than the other lobes), tumor differentiation (OR = 9.93, 95% CI 2.38--41.37; *P* = 0.002, present 11.6% and absent 1.3%), pulmonary membrane invasion (OR = 3.95, 95% CI 1.87--8.34; *P* \< 0.0001, present 21.1% and absent 6.3%), bronchial mucosa and cartilage invasion (OR = 4.84, 95% CI 2.41--9.71; *P* \< 0.0001, present 25.9% and absent 6.7%), vascular invasion (OR = 7.49, 95% CI 3.68--15.26; *P* \< 0.0001, present 34.1% and absent 6.5%), nerve invasion (OR = 3.75, 95% CI 0.98--14.33; *P* = 0.053, present 25.0% and absent 8.2%), CEA (OR = 6.53, 95% CI 2.69--15.82; *P* \< 0.0001, \> 2.21 ng/mL 13.8% and ≤ 2.21 ng/mL 2.4%), and albumin (OR = 0.46, 95% CI 0.25--0.85; *P* = 0.013, ≤43.1 g/L 11.5% and \> 43.1 g/L 5.6%) were the 10 significant risk factors associated with metastasis (Table [4](#Tab4){ref-type="table"}).Table 4Univariate and Multivariate Logistic Regression Predictors of Lobe specific Mediastinal lymph Node MetastasisIndependents VariablesUnivariate PredictorsMultivariate PredictorsN Metastasis/N totalOdds Ratio (95% CI), *P*-valueBOdds Ratio (95% CI), *P*-valueAge (years) ≤6025/298 (8.4%)Reference \> 6025/291 (8.6%)1.03 (0.58--1.83), 0.930Sex Female18/301 (6.0%)Reference Male32/288 (11.1%)1.97 (1.08--3.59), 0.028\*Maximum diameter of tumor ≤1.6 cm10/303 (3.3%)Reference \> 1.6 cm39/279 (14.0%)4.76 (2.33--9.74), \< 0.0001\*1.163.18 (1.15--8.78), 0.026^\#^Position0.096\*0.019^\#^ Right Upper Lobe9/181 (5.0%)Reference Right Middle Lobe4/28 (14.3%)3.19 (0.91--11.15), 0.070\*1.785.92 (0.93--37.66), 0.060 Right Lower Lobe14/84 (16.7%)3.82 (1.58--9.24), 0.003\*2.4211.29 (2.50--51.04), 0.002^\#^ Left Upper Lobe10/135 (7.4%)1.53 (0.60--3.87), 0.3710.061.07 (0.22--5.07), 0.937 Left Lower Lobe7/87 (8.0%)1.67 (0.60--4.65), 0.3241.213.35 (0.78--14.38),0.103 Ipsilateral Mixed lobes4/48 (8.3%)1.74 (0.51--5.91), 0.3761.936.89 (1.16--40.83),0.034^\#^ Bilateral Mixed lobes2/26 (7.7%)1.59 (0.33--7.81), 0.5662.5412.69 (1.65--97.51),0.015^\#^Pathological type Adenocarcinoma41/440 (9.3%)Reference Others9/147 (6.1%)0.64 (0.30--1.34), 0.233Tumor differentiation No2/153 (1.3%)Reference Yes48/413 (11.6%)9.93 (2.38--41.37), 0.002\*Pathological morphology No16/209 (7.7%)Reference Yes33/356 (9.3%)1.23 (0.66--2.30), 0.511Pulmonary membrane invasion No27/427 (6.3%)Reference Yes12/57 (21.1%)3.95 (1.87--8.34), \< 0.0001\*1.534.60 (1.60--13.23),0.005^\#^Bronchial mucosa and cartilage invasion No36/534 (6.7%)Reference Yes14/54 (25.9%)4.84 (2.41--9.71), \< 0.0001\*Vascular invasion No35/542 (6.5%)Reference Yes15/44 (34.1%)7.49 (3.68--15.26), \< 0.0001\*1.353.85 (1.26--11.78), 0.018^\#^Nerve invasion No47/576 (8.2%)Reference Yes3/12 (25.0%)3.75 (0.98--14.33), 0.053\*CEA ≤2.21 ng/ml6/250 (2.4%)Reference \> 2.21 ng/ml35/253 (13.8%)6.53 (2.69--15.82), \< 0.0001\*1.796.01 (1.86--19.44), 0.003^\#^Albumin ≤43.1 g/l33/287 (11.5%)Reference \> 43.1 g/l16/286 (5.6%)0.46 (0.25--0.85), 0.013\*\*Only variables with *P* value less than 0.20 were included in the multivariate analysis. ^**\#**^ *P* \< 0.05 Sum might not always be in total because of missing data

For the lobe nonspecific mediastinal lymph node, univariate analysis indicated that tumor differentiation (OR = 2.68, 95% CI 0.79--9.11; *P* = 0.115, present 5.1% and absent 2.0%), bronchial mucosa and cartilage invasion (OR = 3.58, 95% CI 1.36--9.45; *P* = 0.010, present 11.1% and absent 3.4%), vascular invasion (OR = 7.31, 95% CI 2.93--18.21; *P* \< 0.0001, present 18.2% and absent 3.0%), and nerve invasion (OR = 8.81, 95% CI 2.22--34.93; *P* = 0.002, present 25.0% and absent 3.6%) were the 4 significant risk factors associated with metastasis (Table [5](#Tab5){ref-type="table"}).Table 5Univariate and multivariate logistic regression predictors of lobe non-specific mediastinal lymph node metastasisIndependents VariablesUnivariate PredictorsMultivariate PredictorsN Metastasis/N totalOdds Ratio (95% CI), *P*-valueBOdds Ratio (95% CI), *P*-valueAge (years) ≤6015/298 (5.0%)Reference \> 609/291 (3.1%)0.60 (0.26--1.40), 0.238Sex Female14/301 (4.7%)Reference Male10/288 (3.5%)0.74 (0.32--1.69), 0.471Maximum diameter of tumor ≤1.6 cm9/303 (3.0%)Reference \> 1.6 cm14/279 (5.0%)1.73 (0.74--4.05), 0.210Position0.535 Right Upper Lobe5/181 (2.8%)Reference Right Middle Lobe0/28 (0.0%)0.00 (0.00,) 0.998 Right Lower Lobe7/84 (8.3%)3.20 (0.99--10.40), 0.053 Left Upper Lobe4/135 (3.0%)1.08 (0.28--4.08), 0.916 Left Lower Lobe4/87 (4.6%)1.70 (0.44--6.48), 0.440 Ipsilateral Mixed lobes3/48 (6.3%)2.35 (0.54--10.19), 0.255 Bilateral Mixed lobes1/26 (3.8%)1.41 (0.16--12.55), 0.759Pathological type Adenocarcinoma17/440 (3.9%)Reference Others7/147 (4.8%)1.24 (0.51--3.06), 0.635Tumor differentiation No3/153 (2.0%)Reference Yes21/413 (5.1%)2.68 (0.79--9.11), 0.115\*Pathological morphology No8/209 (3.8%)Reference Yes16/356 (4.5%)1.18 (0.50--2.81), 0.705Pulmonary membrane invasion No15/427 (3.5%)Reference Yes4/57 (7.0%)2.07 (0.66--6.48), 0.210Bronchial mucosa and cartilage invasion No18/534 (3.4%)Reference Yes6/54 (11.1%)3.58 (1.36--9.45), 0.010\*Vascular invasion No16/542 (3.0%)Reference Yes8/44 (18.2%)7.31 (2.93--18.21), \< 0.0001\*1.594.89 (1.78--13.40), 0.002^\#^Nerve invasion No21/576 (3.6%)Reference Yes3/12 (25.0%)8.81 (2.22--34.93), 0.002\*1.554.73 (1.05--21.35), 0.043^\#^CEA ≤2.21 ng/ml8/250 (3.2%)Reference \> 2.21 ng/ml14/253 (5.5%)1.77 (0.73--4.30), 0.206Albumin ≤43.1 g/l12/287 (4..2%)Reference \> 43.1 g/l11/286 (3.8%)0.92 (0.40--2.11), 0.838\*Only variables with *P* value less than 0.20 were included in the multivariate analysis. ^**\#**^ *P* \< 0.05 Sum might not always be in total because of missing data

As for skipping mediastinal lymph node, univariate analysis disclosed that age (OR = 0.38, 95% CI 0.10--1.44; *P* = 0.153, ≤60 2.7% and \> 60 0%), sex (OR = 0.39, 95% CI 0.10--1.47; *P* = 0.162, female patients 2.7% and male patients 1.0%), nerve invasion (OR = 12.60, 95% CI 2.41--65.93; *P* = 0.003, present 16.7% and absent 1.6%), and albumin (OR = 0.34, 95% CI 0.19--0.62; *P* \< 0.0001, \> 43.1 g/L 2.8% and ≤ 43.1 g/L 1.0%) were the 4 significant risk factors associated with metastasis (Table [6](#Tab6){ref-type="table"}).Table 6Univariate and Multivariate Logistic Regression Predictors of Skipping Mediastinal lymph Node MetastasisIndependents VariablesUnivariate PredictorsMultivariate PredictorsN Metastasis/N totalOdds Ratio (95% CI), *P*-valueBOdds Ratio (95% CI), *P*-valueAge (years) ≤608/298 (2.7%)Reference \> 603/291 (0%)0.38 (0.10--1.44), 0.153\*Sex Female8/301 (2.7%)Reference Male3/288 (1.0%)0.39 (0.10--1.47), 0.162\*Maximum diameter of tumor ≤1.6 cm6/303 (2.0%)Reference \> 1.6 cm4/279 (1.4%)0.72 (0.20--2.58), 0.614Position0.961 Right Upper Lobe4/181 (2.2%)Reference Right Middle Lobe0/28 (0.0%)0.00 (0.00,), 0.998 Right Lower Lobe3/84 (3.6%)1.64 (0.36--7.49), 0.524 Left Upper Lobe2/135 (1.5%)0.67 (0.12--3.69), 0.641 Left Lower Lobe1/87 (1.1%)0.52 (0.06--4.67), 0.555 Ipsilateral Mixed lobes1/48 (2.1%)0.94 (0.10--8.62), 0.957 Bilateral Mixed lobes0/26 (0.0%)0.00 (0.00,), 0.998Pathological type Adenocarcinoma7/440 (1.6%)Reference Others4/147 (2.75)1.73 (0.50--6.00), 0.387Tumor differentiation No2/153 (1.3%)Reference Yes9/413 (2.2%)1.68 (0.36--7.87), 0.509Pathological morphology No4/209 (1.9%)Reference Yes7/356 (2.0%)1.03 (0.30--3.55), 0.965Pulmonary membrane invasion No8/427 (1.9%)Reference Yes2/57 (3.5%)1.91 (0.39--9.20), 0.423Bronchial mucosa and cartilage invasion No10/534 (1.9%)Reference Yes1/54 (1.9%)0.99 (0.12--7.87), 0.991Vascular invasion No10/542 (1.8%)Reference Yes1/44 (2.3%)1.24 (0.16--9.89), 0.841Nerve invasion No9/576 (1.6%)Reference Yes2/12 (16.7%)12.60 (2.41--65.93), 0.003\*3.3729.11 (3.81--222.61), 0.001^\#^CEA ≤2.21 ng/ml6/250 (2.4%)Reference \> 2.21 ng/ml5/253 (2.0%)0.82 (0.25--2.72), 0.746Albumin ≤43.1 g/l3/287 (1.0%)Reference \> 43.1 g/l8/286 (2.8%)0.34 (0.19--0.62), \< 0.0001\*1.635.09 (0.99--26.20), 0.051^\#^\*Only variables with *P* value less than 0.20 were included in the multivariate analysis. ^**\#**^ *P* \< 0.05 Sum might not always be in total because of missing data

Multivariable analysis of clinicopathologic characteristics associated with metastasis of different regional lymph nodes {#Sec8}
------------------------------------------------------------------------------------------------------------------------

For the interlobar lymph node, multivariate analysis of the 8 risk factors obtained from univariate analysis suggested that none of them were significant predictors of interlobar lymph node metastasis (Table [2](#Tab2){ref-type="table"}).

For the hilar lymph node, multivariate analysis of the 10 risk factors acquired from univariate analysis showed that only bronchial mucosa and cartilage invasion (absent vs. present, OR = 3.11, 95% CI 1.19--8.13; *P* = 0.021), vascular invasion (absent vs. present, OR = 2.98, 95% CI 1.14--7.81; *P* = 0.026), and CEA (≤2.21 ng/mL vs. \> 2.21 ng/mL, OR = 8.49, 95% CI 2.49--28.97; *P* = 0.001) were the 3 independent predictors associated with metastasis (Table [3](#Tab3){ref-type="table"}).

For the lobe specific mediastinal lymph node, multivariate analysis of the 10 risk factors resulting from univariate analysis indicated that only the maximum diameter of the tumor (≤1.6 cm vs. \> 1.6 cm, OR = 3.18, 95% CI 1.15--8.87; P = 0.026), position (*P* = 0.019), pulmonary membrane invasion (absent vs. present, OR = 4.60, 95% CI 1.60--13.23; *P* = 0.005), vascular invasion (absent vs. present, OR = 3.85, 95% CI 1.26--11.78; *P* = 0.018), and CEA (≤2.21 ng/mL vs. \> 2.21 ng/mL, OR = 6.01, 95% CI 1.86--19.44; *P* = 0.003) were the 5 independent predictors associated with metastasis (Table [4](#Tab4){ref-type="table"}).

For the lobe nonspecific mediastinal lymph node, multivariate analysis of the 4 risk factors obtained from univariate analysis revealed that only vascular (absent vs. present, OR = 4.89, 95% CI 1.78--13.40; *P* = 0.002) and nerve invasions (absent vs. present, OR = 4.73, 95% CI 1.05--21.35; *P* = 0.043) were the 2 independent predictors associated with the presence of metastasis (Table [5](#Tab5){ref-type="table"}).

For the skipping mediastinal lymph node, multivariate analysis of the 4 risk factors derived from univariate analysis established that only nerve invasion (absent vs. present, OR = 29.11, 95% CI 3.81--222.61; *P* = 0.001) and albumin (≤43.1 g/L vs. \> 43.1 g/L, OR = 5.09, 95% CI 0.99--26.20; *P* = 0.051) were the 2 independent predictors associated with the presence of metastasis (Table [6](#Tab6){ref-type="table"}).

Discussion {#Sec9}
==========

Evaluation of regional lymph node metastasis is important for surgeons to determine the treatment and prognosis \[[@CR18]\]. Accordingly, regional lymph node maps have been created to standardize the assessment of metastasis. In these maps, lymph nodes are labeled using a system of numerical levels and assigned names based on their anatomical location \[[@CR19], [@CR20]\]. The International Association for the Study of Lung Cancer (IASLC) lymph node map is employed in the eighth edition of the TNM staging system \[[@CR21]\]. According to the sequence of the lymph node map, lung cancer cells initially spread to the ipsilateral interlobar lymph nodes, then to the hilar lymph nodes, and finally to the mediastinal lymph nodes.

The concept of lobe specific mediastinal lymph nodes is based on the lobe specificity of the lymphatic spread \[[@CR22]\]. In literature, lobe specific MLNs have been defined as 2R, 3, and 4R for the right upper lobe; 3, 7, and 8 for the right lower lobe; 4 L, 5, and 7 for the left upper lobe; and 4 L, 7, and 8 for the left lower lobe. However, Kotoulasa et al. and Shapiro et al. proposed a simpler pattern. Right upper lobe tumors mainly metastasize to 4R, right middle lobe to 4R and 7, right lower lobe to 7, left upper lobe to 5, and left lower lobe to 7 and 9 \[[@CR11], [@CR12]\]. An analysis of the recent literature led to our definitions of lobe specific lymph nodes: 2, 3, and 4 for the right upper lobe; 4 and 7 for the right middle lobe; 7 and 8 for the right lower lobe; 5 and 7 for the left upper lobe; and 7, 8, and 9 for the left lower lobe.

A complete mediastinal lymph node dissection which removes all ipsilateral mediastinal lymph nodes \[[@CR23]\], can provide more accurate pathological staging and improved clinical outcomes for some patients. This approach is considered a standard surgical treatment for patients diagnosed preoperatively with mediastinal lymph node metastases. However, complete mediastinal lymph node dissection is not considered a routine surgical treatment for patients with stage-I NSCLC because of the increased incidence of postoperative complications including increase in blood loss, median operative time, total chest-tube drainage and occurrence rate of chylothorax. The rapid pathological results would help surgeons to make decisions about which patterns should be performed; wedge resection, segmentectomy, or lobectomy. However, surgeons do not know which pattern should be chosen for lymph node dissection and we need some guidance from clinical research. Mark Shapiro et al. further demonstrated the importance of lobe specific MLN regarded as sentinel lymph nodes in mediastinal position in the surgical treatment of early stage lung cancer \[[@CR12]\]. Each patient exhibits different clinicopathologic characteristics that determine the risk for regional lymph node metastasis in early stage lung cancer. We attempted to identify the risk factors to predict lymph node metastasis and allow surgeons to make appropriate decisions on the extent of the dissection. For some early patients, surgeon can remove regional lymph nodes such as lobe specific MLN that are most likely to contain metastases and avoid unnecessary systemic complete lymph nodes dissection in order to accelerate patients' postoperative recovery.

First, we used univariate analysis to ascertain the associations between clinicopathologic factors and regional lymph node metastasis. The results disclosed that sex (male patients), maximum diameter of the tumor (\> 1.6 cm), position (right lower lobe, left lower lobe, and bilateral mixed lobes), pulmonary membrane invasion, bronchial mucosa and cartilage invasion, vascular invasion, CEA (\> 2.21 ng/mL), and albumin (≤43.1 g/L) were the 8 significant risk factors associated with the presence of metastatic interlobar lymph nodes.

Sex (male patients), maximum diameter of the tumor (\> 1.6 cm), position (right lower lobe, right middle lobe, and ipsilateral mixed lobes), tumor differentiation, pulmonary membrane invasion, bronchial mucosa and cartilage invasion, vascular invasion, nerve invasion, CEA (\> 2.21 ng/mL), and albumin (≤43.1 g/L) were the 10 significant risk factors associated with the presence of metastatic hilar lymph nodes.

Sex (male patients), maximum diameter of the tumor (\> 1.6 cm), position (right lower lobe, and right middle lobe), tumor differentiation, pulmonary membrane invasion, bronchial mucosa and cartilage invasion, vascular invasion, nerve invasion, CEA (\> 2.21 ng/mL), and albumin (≤43.1 g/L, 11.5%) were the 10 significant risk factors associated with the presence of metastatic lobe specific mediastinal lymph nodes.

Tumor differentiation, bronchial mucosa and cartilage invasion, vascular invasion, and nerve invasion were the 4 significant risk factors associated with the presence of metastatic lobe nonspecific mediastinal lymph nodes.

Age (≤60), sex (female patients), nerve invasion, and albumin (\> 43.1 g/L) were the 4 significant risk factors associated with the presence of metastatic skipping mediastinal lymph nodes.

Furthermore, multivariate analysis of these factors identified using univariate analysis suggested that all the risk factors were not significant predictors of interlobar lymph node metastasis.

Only bronchial mucosa and cartilage invasion, vascular invasion, and CEA (\> 2.21 ng/mL) were the three independent predictors associated with the presence of metastatic hilar lymph nodes. Therefore, when patients are suspected of having bronchial mucosa and cartilage invasion, vascular invasion, and CEA (\> 2.21 ng/mL), hilar lymph node dissection should probably be performed.

Only maximum diameter of the tumor (\> 1.6 cm), position (right lower lobe, ipsilateral mixed lobes, and bilateral mixed lobes), pulmonary membrane invasion, vascular invasion, and CEA (\> 2.21 ng/mL) were the 5 independent predictors associated with the presence of metastatic lobe specific mediastinal lymph nodes. Hence, when patients are suspected of pulmonary membrane invasion, vascular invasion, CEA (\> 2.21 ng/mL), and tumor (\> 1.6 cm) in the right lower lobe or mixed lobes, lobe specific lymph node dissection should probably be performed.

Only nerve and vascular invasions were the two independent predictors associated with the presence of metastatic lobe nonspecific mediastinal lymph nodes. Hence, when patients are suspected of nerve and vascular invasions, complete mediastinal lymph node dissection should probably be performed.

Only nerve invasion and albumin (\> 43.1 g/L) were the two independent predictors associated with the presence of metastatic skipping mediastinal lymph nodes. Therefore, when patients are suspected of nerve invasion and albumin (\> 43.1 g/L), complete mediastinal lymph node dissection should probably be performed.

These results demonstrate the possibility of changes to lymph node metastasis when a tumor invades different tissues. In early-stage metastasis, the tumor invades bronchial mucosa and cartilage, pulmonary membranes, and vascular tissue only. During this stage, the CEA level (\> 2.21 ng/mL) is likely to be an important predictor indicating that the tumor began to metastasize from the lymphatic system. Therefore, hilar and lobe-specific mediastinal lymph nodes, which are most likely to become the first metastatic stations, should be surgically removed. In later stages of lymph node metastasis, when the tumor begins to invade vascular and neural tissues, the albumin level (\> 43.1 g/L) is likely to be an important predictor that indicates and promotes skip metastasis. When there is an increased possibility of broad mediastinal metastases, a complete mediastinal lymph-node dissection is required to ensure that all suspected metastatic lymph nodes are removed.

However, our study has some limitations. This study was conducted at a single institution with retrospective methods and demonstrated the necessity of further prospective study. Further prospective study with multicenter trial should be performed to comprehensively evaluate clinicopathologic predictors of metastasis of different regional lymph nodes in patients intraoperatively diagnosed with stage-I non-small cell lung cancer.

Conclusions {#Sec10}
===========

After a comprehensive analysis of results concerning the different clinicopathologic factors, we conclude that complete mediastinal lymph node dissection should probably be performed for patients suspected of nerve invasion and albumin (\> 43.1 g/L) or nerve and vascular invasions; lobe specific lymph node dissection should probably be performed for patients suspected of pulmonary membrane invasion, vascular invasion, CEA (\> 2.21 ng/mL), and tumor (\> 1.6 cm) in the right lower lobe or mixed lobes; hilar lymph node dissection should probably be performed for patients suspected of having bronchial mucosa and cartilage invasion, vascular invasion, and CEA (\> 2.21 ng/mL).

Additional file
===============

 {#Sec11}

Additional file 1:Support file containing the Age (G), cigarettes (0:negative, 1:positive), Alcohol (0:negative, 1:positive), chronic bronchitis (0:negative, 1:positive), diabetes (0:negative, 1:positive), tumor history (0:negative, 1:positive), tumor family history (0:negative, 1:positive), blood type (0:A,1:B,2:O,3:AB), Neutrophil(G), Lymphocyte(G), N/L(G), Platelet(G), Serum Albumin(G), ALP(G), Serum Globulin(G), Al/Gl ratio(G), APTT(G), PT(G), CEA(G), CYFRA211(G), NSE(G), Tumor size(G), Tumor location (0:right upper,1:right middle,2:right lower,3:left upper,4:left lower,5:Ipsilateral), Tumor location(G), Pathology (0:AdCa,1:SqCa,2:Adenocarcinoma in situ,3:other), Pathology(G),Grade (G), Pathological morphology (1:lepidic, 2:Acinar, 3:Micropapillary, 4:Papillary, 5:solid), Pathological morphology(G), Pulmonary membrane invasion (0:negative, 1:positive), Bronchial mucosa and cartilage invasion (0:negative, 1:positive), Vascular invasion (0:negative, 1:positive), Nerve invasion (0:negative, 1:positive), Lobe-specific mediastinal lymph nodes (1:metastasis 0:no metastasis),Lobe non-specific mediastinal lymph nodes (1:metastasis 0:no metastasis), skiping mediastinal lymph nodes (1:metastasis 0:no metastasis),2, 4station(1:metastasis 0:no metastasis),5, 6station(1:metastasis 0:no metastasis),7station(1:metastasis 0:no metastasis),8station(1:metastasis 0:no metastasis), 9station(1:metastasis 0:no metastasis), hilar lymph nodes (10 station)(1:metastasis 0:no metastasis), interlobe lymph nodes (11 station)(1,metastasis 0,no metastasis) described in categorical variables and Age ranges (yrs), number of cigarettes, Tumor size (cm). Neutrophil, Lymphocyte, N/L, Platelet, Serum Albumin, ALP, Serum Globulin, Al/Gl ratio, APTT, PT, CEA, CYFRA211, NSE described in continuous variables. (XLSX 173 kb)

CEA

:   Carcinoembryonic antigen

CI

:   Confidence intervals

CT

:   Computed tomography

IASLC

:   Association for the study of lung cancer

MLN

:   Mediastinal lymph node

NCCN

:   National comprehensive cancer network
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:   Non-small-cell lung cancer
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:   Odds ratio
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:   pathological nodal
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